Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Nanoparticles for regenerative medicine.

Pöttler M, Cicha I, Unterweger H, Janko C, Friedrich RP, Alexiou C.

Nanomedicine (Lond). 2019 Aug;14(15):1929-1933. doi: 10.2217/nnm-2019-0162. Epub 2019 Aug 2. No abstract available.

2.

Non-magnetic chromatographic separation of colloidally metastable superparamagnetic iron oxide nanoparticles and suspension cells.

Mühlberger M, Janko C, Unterweger H, Band J, Schreiber E, Lehmann C, Dudziak D, Lee G, Alexiou C, Tietze R.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Aug 1;1122-1123:83-89. doi: 10.1016/j.jchromb.2019.05.033. Epub 2019 May 29.

PMID:
31173996
3.

Functionalized Superparamagnetic Iron Oxide Nanoparticles (SPIONs) as Platform for the Targeted Multimodal Tumor Therapy.

Janko C, Ratschker T, Nguyen K, Zschiesche L, Tietze R, Lyer S, Alexiou C.

Front Oncol. 2019 Feb 13;9:59. doi: 10.3389/fonc.2019.00059. eCollection 2019.

4.

Magnetic Tissue Engineering of the Vocal Fold Using Superparamagnetic Iron Oxide Nanoparticles.

Pöttler M, Fliedner A, Bergmann J, Bui LK, Mühlberger M, Braun C, Graw M, Janko C, Friedrich O, Alexiou C, Lyer S.

Tissue Eng Part A. 2019 May 2. doi: 10.1089/ten.TEA.2019.0009. [Epub ahead of print]

PMID:
30747035
5.

Cellular effects of paclitaxel-loaded iron oxide nanoparticles on breast cancer using different 2D and 3D cell culture models.

Lugert S, Unterweger H, Mühlberger M, Janko C, Draack S, Ludwig F, Eberbeck D, Alexiou C, Friedrich RP.

Int J Nanomedicine. 2018 Dec 21;14:161-180. doi: 10.2147/IJN.S187886. eCollection 2019.

6.

Nanomedicine for neuroprotection.

Friedrich RP, Pöttler M, Cicha I, Unterweger H, Janko C, Alexiou C.

Nanomedicine (Lond). 2019 Jan;14(2):127-130. doi: 10.2217/nnm-2018-0401. Epub 2018 Dec 10. No abstract available.

PMID:
30526308
7.

SPIONs functionalized with small peptides for binding of lipopolysaccharide, a pathophysiologically relevant microbial product.

Karawacka W, Janko C, Unterweger H, Mühlberger M, Lyer S, Taccardi N, Mokhir A, Jira W, Peukert W, Boccaccini AR, Kolot M, Strauss R, Bogdan C, Alexiou C, Tietze R.

Colloids Surf B Biointerfaces. 2019 Feb 1;174:95-102. doi: 10.1016/j.colsurfb.2018.11.002. Epub 2018 Nov 3.

PMID:
30445255
8.

Inert Coats of Magnetic Nanoparticles Prevent Formation of Occlusive Intravascular Co-aggregates With Neutrophil Extracellular Traps.

Bilyy R, Unterweger H, Weigel B, Dumych T, Paryzhak S, Vovk V, Liao Z, Alexiou C, Herrmann M, Janko C.

Front Immunol. 2018 Oct 2;9:2266. doi: 10.3389/fimmu.2018.02266. eCollection 2018.

9.

ROS-Responsive N-Alkylaminoferrocenes for Cancer-Cell-Specific Targeting of Mitochondria.

Reshetnikov V, Daum S, Janko C, Karawacka W, Tietze R, Alexiou C, Paryzhak S, Dumych T, Bilyy R, Tripal P, Schmid B, Palmisano R, Mokhir A.

Angew Chem Int Ed Engl. 2018 Sep 10;57(37):11943-11946. doi: 10.1002/anie.201805955. Epub 2018 Aug 20.

PMID:
30035345
10.

Targeting of drug-loaded nanoparticles to tumor sites increases cell death and release of danger signals.

Alev M, Egenberger L, Mühleisen L, Weigel B, Frey B, Friedrich RP, Pöttler M, Alexiou C, Janko C.

J Control Release. 2018 Sep 10;285:67-80. doi: 10.1016/j.jconrel.2018.07.007. Epub 2018 Jul 4. No abstract available.

PMID:
30008372
11.

'Nano-lysing' the disease process: novel diagnostic and therapeutic nanoparticles.

Janko C, Friedrich RP, Pöttler M, Cicha I, Lyer S, Unterweger H, Alexiou C.

Nanomedicine (Lond). 2018 May;13(10):1087-1091. doi: 10.2217/nnm-2018-0061. Epub 2018 Jun 6. No abstract available.

PMID:
29874148
12.

Dextran-coated superparamagnetic iron oxide nanoparticles for magnetic resonance imaging: evaluation of size-dependent imaging properties, storage stability and safety.

Unterweger H, Dézsi L, Matuszak J, Janko C, Poettler M, Jordan J, Bäuerle T, Szebeni J, Fey T, Boccaccini AR, Alexiou C, Cicha I.

Int J Nanomedicine. 2018 Mar 28;13:1899-1915. doi: 10.2147/IJN.S156528. eCollection 2018.

13.

Elevated Serum Lysophosphatidylcholine in Patients with Systemic Lupus Erythematosus Impairs Phagocytosis of Necrotic Cells In Vitro.

Grossmayer GE, Keppeler H, Boeltz S, Janko C, Rech J, Herrmann M, Lauber K, Muñoz LE.

Front Immunol. 2018 Jan 17;8:1876. doi: 10.3389/fimmu.2017.01876. eCollection 2017.

14.

Treat or track: nanoagents in the service of health.

Lyer S, Janko C, Friedrich RP, Pöttler M, Cicha I, Alexiou C.

Nanomedicine (Lond). 2017 Dec;12(24):2715-2719. doi: 10.2217/nnm-2017-0293. Epub 2017 Nov 3. No abstract available.

15.

The involvement of E6, p53, p16, MDM2 and Gal-3 in the clinical outcome of patients with cervical cancer.

Stiasny A, Freier CP, Kuhn C, Schulze S, Mayr D, Alexiou C, Janko C, Wiest I, Dannecker C, Jeschke U, Kost BP.

Oncol Lett. 2017 Oct;14(4):4467-4476. doi: 10.3892/ol.2017.6752. Epub 2017 Aug 14.

16.

Tuning the structure of aminoferrocene-based anticancer prodrugs to prevent their aggregation in aqueous solution.

Daum S, Babiy S, Konovalova H, Hofer W, Shtemenko A, Shtemenko N, Janko C, Alexiou C, Mokhir A.

J Inorg Biochem. 2018 Jan;178:9-17. doi: 10.1016/j.jinorgbio.2017.08.038. Epub 2017 Sep 15.

PMID:
29028541
17.

Lysosome-Targeting Amplifiers of Reactive Oxygen Species as Anticancer Prodrugs.

Daum S, Reshetnikov MSV, Sisa M, Dumych T, Lootsik MD, Bilyy R, Bila E, Janko C, Alexiou C, Herrmann M, Sellner L, Mokhir A.

Angew Chem Int Ed Engl. 2017 Dec 4;56(49):15545-15549. doi: 10.1002/anie.201706585. Epub 2017 Nov 9.

PMID:
28994179
18.

[1,10]Phenanthroline based cyanine dyes as fluorescent probes for ribonucleic acids in live cells.

Kovalska V, Kuperman M, Varzatskii O, Kryvorotenko D, Kinski E, Schikora M, Janko C, Alexiou C, Yarmoluk S, Mokhir A.

Methods Appl Fluoresc. 2017 Oct 24;5(4):045002. doi: 10.1088/2050-6120/aa8510.

PMID:
28790236
19.

Non-immunogenic dextran-coated superparamagnetic iron oxide nanoparticles: a biocompatible, size-tunable contrast agent for magnetic resonance imaging.

Unterweger H, Janko C, Schwarz M, Dézsi L, Urbanics R, Matuszak J, Őrfi E, Fülöp T, Bäuerle T, Szebeni J, Journé C, Boccaccini AR, Alexiou C, Lyer S, Cicha I.

Int J Nanomedicine. 2017 Jul 24;12:5223-5238. doi: 10.2147/IJN.S138108. eCollection 2017.

20.

Analysis of Hypericin-Mediated Effects and Implications for Targeted Photodynamic Therapy.

Mühleisen L, Alev M, Unterweger H, Subatzus D, Pöttler M, Friedrich RP, Alexiou C, Janko C.

Int J Mol Sci. 2017 Jun 29;18(7). pii: E1388. doi: 10.3390/ijms18071388.

21.

Synthesis of Magnetic-Nanoparticle/Ansamitocin Conjugates-Inductive Heating Leads to Decreased Cell Proliferation In Vitro and Attenuation Of Tumour Growth In Vivo.

Seidel K, Balakrishnan A, Alexiou C, Janko C, Komoll RM, Wang LL, Kirschning A, Ott M.

Chemistry. 2017 Sep 7;23(50):12326-12337. doi: 10.1002/chem.201701491. Epub 2017 Jul 31.

PMID:
28585348
22.

Altered glycan accessibility on native immunoglobulin G complexes in early rheumatoid arthritis and its changes during therapy.

Stümer J, Biermann MHC, Knopf J, Magorivska I, Kastbom A, Svärd A, Janko C, Bilyy R, Schett G, Sjöwall C, Herrmann M, Muñoz LE.

Clin Exp Immunol. 2017 Sep;189(3):372-382. doi: 10.1111/cei.12987. Epub 2017 Jun 13.

23.

Selection of potential iron oxide nanoparticles for breast cancer treatment based on in vitro cytotoxicity and cellular uptake.

Poller JM, Zaloga J, Schreiber E, Unterweger H, Janko C, Radon P, Eberbeck D, Trahms L, Alexiou C, Friedrich RP.

Int J Nanomedicine. 2017 Apr 19;12:3207-3220. doi: 10.2147/IJN.S132369. eCollection 2017.

24.

Impact of Superparamagnetic Iron Oxide Nanoparticles on Vocal Fold Fibroblasts: Cell Behavior and Cellular Iron Kinetics.

Pöttler M, Fliedner A, Schreiber E, Janko C, Friedrich RP, Bohr C, Döllinger M, Alexiou C, Dürr S.

Nanoscale Res Lett. 2017 Dec;12(1):284. doi: 10.1186/s11671-017-2045-5. Epub 2017 Apr 20.

25.

Magnetic nanoparticles for medical applications.

Cicha I, Lyer S, Janko C, Friedrich RP, Pöttler M, Alexiou C.

Nanomedicine (Lond). 2017 Apr;12(8):825-829. doi: 10.2217/nnm-2017-0038. Epub 2017 Mar 24. No abstract available.

26.

Journal watch: diagnostic nanoparticles.

Pöttler M, Cicha I, Lyer S, Janko C, Friedrich RP, Alexiou C.

Nanomedicine (Lond). 2017 Feb;12(3):181-184. doi: 10.2217/nnm-2016-0339. Epub 2017 Jan 17. No abstract available.

27.

Nanoparticles size-dependently initiate self-limiting NETosis-driven inflammation.

Muñoz LE, Bilyy R, Biermann MH, Kienhöfer D, Maueröder C, Hahn J, Brauner JM, Weidner D, Chen J, Scharin-Mehlmann M, Janko C, Friedrich RP, Mielenz D, Dumych T, Lootsik MD, Schauer C, Schett G, Hoffmann M, Zhao Y, Herrmann M.

Proc Natl Acad Sci U S A. 2016 Oct 4;113(40):E5856-E5865. Epub 2016 Sep 19.

28.

Immunohistochemical Evaluation of E6/E7 HPV Oncoproteins Staining in Cervical Cancer.

Stiasny A, Kuhn C, Mayr D, Alexiou C, Janko C, Wiest I, Jeschke U, Kost B.

Anticancer Res. 2016 Jun;36(6):3195-8.

PMID:
27272848
29.

Effect of BSA-coated Superparamagnetic Iron Oxide Nanoparticles on Granulosa Cells.

Pöttler M, Hofmann S, Dürr S, Unterweger H, Wiest I, Zaloga J, Alexiou C, Jeschke U, Janko C.

Anticancer Res. 2016 Jun;36(6):3147-54.

PMID:
27272840
30.

Immunohistochemical Evaluation of the Role of p53 Mutation in Cervical Cancer: Ser-20 p53-Mutant Correlates with Better Prognosis.

Freier CP, Stiasny A, Kuhn C, Mayr D, Alexiou C, Janko C, Wiest I, Jeschke U, Kost B.

Anticancer Res. 2016 Jun;36(6):3131-7.

PMID:
27272838
31.

Toxicity of Mitoxantrone-loaded Superparamagnetic Iron Oxide Nanoparticles in a HT-29 Tumour Spheroid Model.

Hornung A, Poettler M, Friedrich RP, Weigel B, Duerr S, Zaloga J, Cicha I, Alexiou C, Janko C.

Anticancer Res. 2016 Jun;36(6):3093-101.

PMID:
27272833
32.

Magnetic Tissue Engineering for Voice Rehabilitation - First Steps in a Promising Field.

Dürr S, Bohr C, Pöttler M, Lyer S, Friedrich RP, Tietze R, Döllinger M, Alexiou C, Janko C.

Anticancer Res. 2016 Jun;36(6):3085-91.

PMID:
27272832
33.

Facile preparation of multifunctional superparamagnetic PHBV microspheres containing SPIONs for biomedical applications.

Li W, Jan Zaloga, Ding Y, Liu Y, Janko C, Pischetsrieder M, Alexiou C, Boccaccini AR.

Sci Rep. 2016 Mar 23;6:23140. doi: 10.1038/srep23140.

34.

Novel nanoparticulate drug delivery systems.

Friedrich RP, Pöttler M, Cicha I, Lyer S, Janko C, Alexiou C.

Nanomedicine (Lond). 2016 Mar;11(6):573-6. doi: 10.2217/nnm.16.18. Epub 2016 Feb 25. No abstract available.

35.

Hypericin-bearing magnetic iron oxide nanoparticles for selective drug delivery in photodynamic therapy.

Unterweger H, Subatzus D, Tietze R, Janko C, Poettler M, Stiegelschmitt A, Schuster M, Maake C, Boccaccini AR, Alexiou C.

Int J Nanomedicine. 2015 Nov 12;10:6985-96. doi: 10.2147/IJN.S92336. eCollection 2015.

36.

Sialylation of anti-histone immunoglobulin G autoantibodies determines their capabilities to participate in the clearance of late apoptotic cells.

Magorivska I, Muñoz LE, Janko C, Dumych T, Rech J, Schett G, Nimmerjahn F, Bilyy R, Herrmann M.

Clin Exp Immunol. 2016 Apr;184(1):110-7. doi: 10.1111/cei.12744. Epub 2016 Jan 27.

37.

Genotoxicity of Superparamagnetic Iron Oxide Nanoparticles in Granulosa Cells.

Pöttler M, Staicu A, Zaloga J, Unterweger H, Weigel B, Schreiber E, Hofmann S, Wiest I, Jeschke U, Alexiou C, Janko C.

Int J Mol Sci. 2015 Nov 3;16(11):26280-90. doi: 10.3390/ijms161125960.

38.

Nanomedical innovation: the SEON-concept for an improved cancer therapy with magnetic nanoparticles.

Lyer S, Tietze R, Unterweger H, Zaloga J, Singh R, Matuszak J, Poettler M, Friedrich RP, Duerr S, Cicha I, Janko C, Alexiou C.

Nanomedicine (Lond). 2015;10(21):3287-304. doi: 10.2217/nnm.15.159. Epub 2015 Oct 16.

39.

Treatment Efficiency of Free and Nanoparticle-Loaded Mitoxantrone for Magnetic Drug Targeting in Multicellular Tumor Spheroids.

Hornung A, Poettler M, Friedrich RP, Zaloga J, Unterweger H, Lyer S, Nowak J, Odenbach S, Alexiou C, Janko C.

Molecules. 2015 Sep 30;20(10):18016-30. doi: 10.3390/molecules201018016.

40.

Magnetic nanoparticle-based drug delivery for cancer therapy.

Tietze R, Zaloga J, Unterweger H, Lyer S, Friedrich RP, Janko C, Pöttler M, Dürr S, Alexiou C.

Biochem Biophys Res Commun. 2015 Dec 18;468(3):463-70. doi: 10.1016/j.bbrc.2015.08.022. Epub 2015 Aug 10. Review.

PMID:
26271592
41.

Recent nanomedicine articles of outstanding interest: nanoparticle functionalization for disease diagnostics and therapy.

Janko C, Pöttler M, Friedrich RP, Lyer S, Cicha I, Alexiou C.

Nanomedicine (Lond). 2015 Jul;10(14):2133-7. doi: 10.2217/nnm.15.98. No abstract available.

42.

The Pathogenicity of Anti-β2GP1-IgG Autoantibodies Depends on Fc Glycosylation.

Fickentscher C, Magorivska I, Janko C, Biermann M, Bilyy R, Nalli C, Tincani A, Medeghini V, Meini A, Nimmerjahn F, Schett G, Muñoz LE, Andreoli L, Herrmann M.

J Immunol Res. 2015;2015:638129. doi: 10.1155/2015/638129. Epub 2015 Jun 22.

43.

Flow cytometry for intracellular SPION quantification: specificity and sensitivity in comparison with spectroscopic methods.

Friedrich RP, Janko C, Poettler M, Tripal P, Zaloga J, Cicha I, Dürr S, Nowak J, Odenbach S, Slabu I, Liebl M, Trahms L, Stapf M, Hilger I, Lyer S, Alexiou C.

Int J Nanomedicine. 2015 Jun 26;10:4185-201. doi: 10.2147/IJN.S82714. eCollection 2015.

44.

Different storage conditions influence biocompatibility and physicochemical properties of iron oxide nanoparticles.

Zaloga J, Janko C, Agarwal R, Nowak J, Müller R, Boccaccini AR, Lee G, Odenbach S, Lyer S, Alexiou C.

Int J Mol Sci. 2015 Apr 24;16(5):9368-84. doi: 10.3390/ijms16059368.

45.

Highlights from the latest articles in nanoparticles, nanomaterials and nanotoxicity testing.

Lyer S, Cicha I, Friedrich RP, Janko C, Alexiou C.

Nanomedicine (Lond). 2015 Jan;10(2):181-4. doi: 10.2217/nnm.14.207. No abstract available.

PMID:
25600964
46.

The progression of cell death affects the rejection of allogeneic tumors in immune-competent mice - implications for cancer therapy.

Chaurio RA, Muñoz LE, Maueröder C, Janko C, Harrer T, Fürnrohr BG, Niederweis M, Bilyy R, Schett G, Herrmann M, Berens C.

Front Immunol. 2014 Nov 11;5:560. doi: 10.3389/fimmu.2014.00560. eCollection 2014.

47.

Altered glycosylation of complexed native IgG molecules is associated with disease activity of systemic lupus erythematosus.

Sjöwall C, Zapf J, von Löhneysen S, Magorivska I, Biermann M, Janko C, Winkler S, Bilyy R, Schett G, Herrmann M, Muñoz LE.

Lupus. 2015 May;24(6):569-81. doi: 10.1177/0961203314558861. Epub 2014 Nov 11.

PMID:
25389233
48.

Development of a lauric acid/albumin hybrid iron oxide nanoparticle system with improved biocompatibility.

Zaloga J, Janko C, Nowak J, Matuszak J, Knaup S, Eberbeck D, Tietze R, Unterweger H, Friedrich RP, Duerr S, Heimke-Brinck R, Baum E, Cicha I, Dörje F, Odenbach S, Lyer S, Lee G, Alexiou C.

Int J Nanomedicine. 2014 Oct 20;9:4847-66. doi: 10.2147/IJN.S68539. eCollection 2014.

49.

Development and characterization of magnetic iron oxide nanoparticles with a cisplatin-bearing polymer coating for targeted drug delivery.

Unterweger H, Tietze R, Janko C, Zaloga J, Lyer S, Dürr S, Taccardi N, Goudouri OM, Hoppe A, Eberbeck D, Schubert DW, Boccaccini AR, Alexiou C.

Int J Nanomedicine. 2014 Aug 5;9:3659-76. doi: 10.2147/IJN.S63433. eCollection 2014.

50.

Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines.

Schauer C, Janko C, Munoz LE, Zhao Y, Kienhöfer D, Frey B, Lell M, Manger B, Rech J, Naschberger E, Holmdahl R, Krenn V, Harrer T, Jeremic I, Bilyy R, Schett G, Hoffmann M, Herrmann M.

Nat Med. 2014 May;20(5):511-7. doi: 10.1038/nm.3547. Epub 2014 Apr 28.

PMID:
24784231

Supplemental Content

Support Center